ZYBERNO
Stock Report
Updated Aug 31, 2026

ALX ONCOLOGY HOLDINGS INC (ALXO)

Healthcare • NASDAQ

$2.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
ALX ONCOLOGY HOLDINGS INC (ALXO) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-90.3%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.08x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-49.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

ALX ONCOLOGY HOLDINGS INC (ALXO) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, ALXO generated -$78.33M in Owner Earnings. Capital was deployed as follows: $202.00K invested in capital expenditures. Reinvestment rate: 4.8%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.00
Market Cap:$271.28M

Valuation Multiples (2)

P/B Ratio:1.99x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$260.80M

Price Action & Momentum (1)

% of 52-Week High:75.2%
B. Profitability Assessment

Return Metrics (5)

ROA:-67.3%
Reinvestment Rate:4.8%
Fundamental Growth Rate (g):-2.4%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$56.78
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:70.3%
Latest Earnings Filed:2026-08-06
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:9.71x
Quick Ratio:9.71x
Cash Ratio:1.54x

Leverage Analysis (3)

Debt To Equity Ttm:0.08x
Debt-to-Equity Ratio:0.08x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-73.93x
Times Interest Earned:-73.93

Capital Structure (4)

Working Capital:128,681,000.00
Cash And Cash Equivalents:22,687,000.00
Long Term Debt:$9.71M
Net Debt:-$10.48M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$82.55M

Bottom Line Performance (3)

-$80.89M
Income Before Tax:-$83.48M
Ebitda Ttm:-81,998,000.00

Operating Expenses (5)

Operating Expenses:82,552,000.00
R And D Expense:61,830,000.00
Sga Expense:20,960,000.00
Income Tax Expense:-$21.00K
Interest Expense:1,407,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$160.82M
Current Assets:$143.46M
Ppe Net:1,104,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:24,633,000.00
Current Liabilities:14,776,000.00
Long Term Debt:$9.71M
Short Term Debt:$2.50M

Equity & Capital (3)

Equity:$136.19M
Retained Earnings:-$758.72M
Common Stock:1,000,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:3,022,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:2,683,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$78.13M-$78.33M

Investment Activities (2)

Investing Cash Flow:-$105.04M
Capital Expenditures Ttm:202,000.00

Financing Activities (3)

Financing Cash Flow:$139.60M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:11,000.00
Long Term Debt Issuance:$10.00M
Long Term Debt Repayments:$1.31M

Non-Cash Items (1)

Depreciation Amortization Ttm:554,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.13
-$1.13
Earnings Per Share Ttm:-$0.60

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.62

Book Value & Capital (2)

Book Value Per Share:$1.00
Cash Per Share:0.17

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$78.33M

Damodaran Growth Analysis (2)

Reinvestment Rate:4.8%
Fundamental Growth Rate (g):-2.4%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-33.1%
C. Company Profile & Context

Corporate Information (6)

Symbol:ALXO
Company Name:ALX ONCOLOGY HOLDINGS INC
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:135.64M
Shares Outstanding Basic:135.64M
Shares Outstanding Diluted:135.64M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 07:46:12 UTC
Data Timestamp:2026-08-18T20:25:54.458030
Scroll to Top